Selected article for: "combination therapy and prospective study"
Author: Peri, Anna Maria; Verna, Marta; Biffi, Stefano; Alagna, Laura; Longhi, Benedetta; Migliorino, Guglielmo Marco; Foresti, Sergio; Bandera, Alessandra; Rovelli, Attilio; Rizzari, Carmelo; Gori, Andrea; Colombini, Antonella
Title: Combination Antifungal Therapy for Invasive Mold Infections Among Pediatric Patients with Hematological Malignancies: Data from A Real-Life Case-Series
  • Document date: 2019_9_5
    • ID: 1egushdn_30
    Snippet: Despite the lack of well-designed trials assessing the efficacy and safety of this approach, combination antifungal regimens are widely used in real-life pediatric settings as reported by several studies. Monocentric surveys on IMI in immunocompromised children reported the use of combination therapy in a percentage of cases ranging from 32% to 92% [2] [3] [4] . A multicenter cohort study performed by Burgos et al, involving 6 US pediatric center.....
    Document: Despite the lack of well-designed trials assessing the efficacy and safety of this approach, combination antifungal regimens are widely used in real-life pediatric settings as reported by several studies. Monocentric surveys on IMI in immunocompromised children reported the use of combination therapy in a percentage of cases ranging from 32% to 92% [2] [3] [4] . A multicenter cohort study performed by Burgos et al, involving 6 US pediatric centers, reported the use of combination regimens in up to 80% of IMI [1] . Moreover, a multicenter international prospective cohort study on mucormycosis by Pana et al reported the use of first-line combination therapy in 53% of cases [6] .

    Search related documents:
    Co phrase search for related documents
    • approach safety efficacy and pediatric center: 1
    • approach safety efficacy and pediatric setting: 1, 2
    • cohort study and combination therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cohort study and design trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • cohort study and line combination therapy: 1
    • cohort study and pediatric center: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • cohort study and pediatric setting: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • cohort study and prospective cohort study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • combination therapy and design trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • combination therapy and line combination therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • combination therapy and pediatric center: 1, 2, 3
    • combination therapy and pediatric setting: 1
    • combination therapy and prospective cohort study: 1, 2, 3
    • design trial and pediatric center: 1
    • design trial and pediatric setting: 1
    • design trial and prospective cohort study: 1, 2, 3, 4, 5, 6
    • pediatric center and prospective cohort study: 1, 2, 3, 4